First- and second-generation family cancer history essential

Share this content:
First- and Second-Generation Family Hx Adequate in Oncology
First- and Second-Generation Family Hx Adequate in Oncology

(HealthDay News) -- Recommendations relating to the key elements of minimum adequate cancer family history are detailed, although they are often incompletely implemented, according to a recommendation statement and related study published online Feb. 3 in the Journal of Clinical Oncology.

Noting that family history can affect long- and short-term cancer management, Karen H. Lu, M.D., from the MD Anderson Cancer Center in Houston, and colleagues made recommendations about a minimum adequate family history for patients with cancer. The researchers note that a minimum adequate family history should include a history of cancer in first- and second-degree relatives. For each relative with cancer, the type of primary cancer, age at diagnosis, and lineage should be recorded. Patients should be asked about known hereditary predisposition information, the results of genetic testing among relatives, and relevant information regarding ethnicity.

In a related study, Marie E. Wood, M.D., from the University of Vermont in Burlington, and colleagues examined the quality of cancer family history (CFH) and genetic counseling/testing practices in 212 practices participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative. The researchers found that 77.4 percent of all medical records reviewed documented the presence or absence of CFH in first-degree relatives and 61.5 percent did so in second-degree relatives, with significantly higher documentation for breast than colorectal cancer. Of patients with increased risk for hereditary cancer, 52.2 and 26.4 percent of those with breast and colorectal cancer, respectively, were referred for genetic counseling/testing.

"Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed," Wood and colleagues write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Statement (subscription or payment may be required)
Abstract - Wood
Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs